Skip to content
#gene editing Open access

Click-Chemistry Functionalized Lipid Nanoparticles for In Vitro and In Vivo Transfection of Primary Human CD4+ T Cells.

Sep 2026 · Advanced Healthcare Materials · pp. e71747 · 0 citations · 31 references
Medicine

TL;DR

A modular DBCO-azide click-chemistry approach is developed to functionalize LNPs with a high-affinity CD4 nanobody, enabling precise CD4 receptor-directed delivery to human CD4+ T cells, establishing CD4-nanobody LNPs as a versatile platform for targeted mRNA and gene-editing delivery.

Abstract

CD4+ T cells orchestrate adaptive immunity and strategies that enable their genetic reprogramming hold promise for treating cancer, immune dysregulation and infectious diseases such as HIV. However, current T cell engineering approaches rely heavily on ex vivo manipulation, which is labor-intensive, costly, and can alter cell phenotypes. Lipid nanoparticles (LNPs) offer a scalable nonviral alternative, yet conventional formulations show minimal interaction with lymphocytes and are rapidly cleared by the liver. In this study, we develop a modular DBCO-azide click-chemistry approach to functionalize LNPs with a high-affinity CD4 nanobody, enabling precise CD4 receptor-directed delivery to human CD4+ T cells. Optimized CD4-targeted LNPs transfect up to 48% of non-activated CD4+ T cells within a PBMC co-culture, the highest efficiency reported so far through LNP transfection. Moreover, they successfully deliver CRISPR-Cas9 components to activated CD4+ T cells and achieve up to 32% gene editing. In humanized NSG-SGM3 mice, CD4-targeted LNPs selectively associate with and transfect circulating and bone marrow-resident human CD4+ T cells while showing minimal off-target activity in murine cells. These results establish CD4-nanobody LNPs as a versatile platform for targeted mRNA and gene-editing delivery, with broad potential for cancer immunotherapy, T cell reprogramming, and HIV cure strategies.

Read PDF

Similar papers

#gene editing Review Open access Sep 2026

Targeted delivery platforms for in vivo immune cell engineering: emerging strategies for cancer immunotherapy

Cancer immunotherapy is a transformative technology allowing for the elimination of malignant cells through immune system stimulation; however, the large-scale clinical application of adoptive cellular therapy technologies is limited due to difficulties in ex vivo immune cell engineering, high costs, and complicated ma...

Hari Krishnareddy Rachamala, Sandeep Atla, R. S. Angom · 0 citations
Open access Oct 2026

LGA-PEI nanoparticles enable efficient nucleic acid delivery to primary murine T cells.

Non-viral engineering of primary T cells is constrained by low transfection efficiency and significant cargo-induced toxicity. This study evaluates a LGA-PEI (lactic-co-glycolic acid-modified polyethyleneimine) nanoparticle system designed to overcome the recalcitrance of murine T cells, particularly unstimulated, muri...

Priscila Tonon Baschirotto, Christian Marín-Müller, Randall Loaiza-Montoya · 0 citations
Oct 2026

Click Chemistry-Mediated Functionalization of Engineered Oncolytic Extracellular Vesicles Promotes Coordinated T- and B-Cell Antitumor Immunity.

Engineered extracellular vesicles (EVs) are promising therapeutic carriers for cancer treatment, but preserving intrinsic therapeutic activity while incorporating multiple immunomodulatory functions remains a challenge. Here, we developed a modular engineering strategy that combines the genetic engineering of EV-produc...

Wen-Mo Liu, Ying Yang, Li-Ying Wang et al. · 0 citations
Open access Sep 2026

Dual-targeted nanoparticles enable the ex vivo generation of cytotoxic and phagocytic CAR effector cells

Chimeric antigen receptor (CAR)-T cells and CAR-macrophages (or CAR-monocytes) offer complementary antitumor functions. CAR-T cells exert potent cytotoxicity against cancer cells, whereas CAR-macrophages can infiltrate solid tumors, phagocytose cancer cells and promote antigen spreading. Antibody-conjugated lipid nanop...

Ji-Su Hong, Jinwoong Lim, Minho Park et al. · 0 citations
Open access Oct 2026

Lipid Nanoparticle Delivery of CAR276 mRNA Enables Antigen-Specific Cytotoxicity in T Cells Against Glioblastoma Cells

Background/Objectives: Glioblastoma multiforme (GBM) remains the most aggressive and treatment-refractory primary brain tumor, with current therapeutic modalities providing minimal survival improvement. Chimeric antigen receptor (CAR)-based immunotherapies succeeded in hematologic malignancies but are constrained in so...

Fatemeh Zahedipour, Sogand Sadeghianfard, Silas Wisser et al. · 0 citations

Related blog posts

Microsoft Research Blog Nov 12, 2026

Microsoft Research Focus – Edition #98

What's new in research at Microsoft? Host Anson Ho explores the latest, including AI-powered universal translation, a breakthrough in a 31-year-old mathematics challenge, and advances making AI coding agents faster and more efficient.  The post Microsoft Research Focus – Edition #98 appeared first on Microsoft Research.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.